Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Blaikley, J. Gibbs, A. Loudon, S. Farrow, D. Singh, D. Ray (Manchester, Stevenage, United Kingdom). Reverbα is a novel regulator of COPD macrophage inflammation and glucocorticoid resistance. Eur Respir J 2011; 38: Suppl. 55, 3849

Member's Comments

No comment yet.

Related content which might interest you: Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 Role of cytokines in regulation of inflammatory and protective reactions in progression of pulmonary MDR tuberculosis Source: Annual Congress 2007 - New methods to diagnose tuberculosis infection and disease and problems in tuberculosis care Year: 2007 T-cell susceptibility to glucocorticoid (GC)-induced apoptosis: the role in asthma pathogenesis and therapy Source: Eur Respir J 2006; 28: Suppl. 50, 227s Year: 2006 Impaired lung function is associated with systemic inflammation and macrophage activation Source: Eur Respir J 2015; 45: 557-559 Year: 2015 Toll-like receptor (TLR)-signaling mediates enhanced inflammatory effects in coinfections of viral and bacterial respiratory pathogens in human lung tissue – A new approach to the pathogenesis of COPD exacerbations? Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 Lung expression of a novel mediator of bacterial inflammation: TREM-1 Source: Eur Respir J 2001; 18: Suppl. 33, 80s Year: 2001 Different inhaled corticosteroids altered lung microbiome and regulating the expression of PAF receptor as well as the phagocytosis function of macrophage Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 A dual role of IL-6 signalling and STAT-3 activation on airway inflammation versus airway hyperresponsiveness in a murine model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002 Characterization of the Toll-IL-1 pathway gene profile in an in-vitro model of chronic airway inflammation Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence Year: 2007 Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases Source: Eur Respir J 2008; 32: 1068-1081 Year: 2008 Soluble ADAM33 augments the pulmonary innate immune response promoting susceptibility to allergic airway inflammation Source: International Congress 2018 – Translational models of the immunopathology that underlies airway obstructive diseases Year: 2018 YI01 - Follistatin-like 1: a crucial factor in lung development and a novel regulator of airway remodelling Source: Lung Science Conference 2012 - Rebuilding a diseased lung: Repair and regeneration Year: 2012 Overexpression of suppressor of cytokine signaling-5 augments eosinophilic inflammation in an asthma model Source: Eur Respir J 2004; 24: Suppl. 48, 348s Year: 2004 Regulation of alternative macrophage activation by galectin-3; potential role in lung fibrosis Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Selective decoy-mediated inhibition of activator protein-1 activity in the airways prevents experimental asthmatic inflammation Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005 The role of the epigenetic regulator HMGN5 in COPD resulting from chronic lung injury Source: ERS Lung Science Conference 2017 Year: 2017 TSPO a new anti-inflammatory target in the airway of COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 The GPx1-PTP1B-PP2A axis: A key determinant of airway inflammation and alveolar destruction Source: Annual Congress 2013 –Acute lung injury: novel clinical and experimental insights Year: 2013 Inhibition of the alternative complement pathway abolishes the development of airway hyperresponsiveness (AHR) and inflammation Source: Eur Respir J 2004; 24: Suppl. 48, 348s Year: 2004 MiR-320d as a regulator of airway inflammation in COPD Source: ERS Lung Science Conference 2020 Year: 2020